Connect with us

Cannabis News

Regulatory shifts reshape Thai cannabis: compliant operators emerge stronger

Published

5 months ago

on

Thai cannabis industries are browsing a speedy regulation shift period, and the operators who expected to meet the start are finding themselves better. “When new rules in GACP entered, we didn’t affect,” says Natcha Klahan, COO in the World Pharma Solutions. “But for many farms, it was a shock. It is a thing that passes the certificate, but it is a real role doing these standards day before day.”

© World Pharma Solutions

Adherence to high rules from the beginning
World Pharma has two GACP certified facilities near Bangkok: Samut Prakan’s high production area, and focused genetics at Samut Sakhon.

Samut Prakan delivers 160-180 kg flowers every three weeks. The farmhouse uses a vertical double tie incinerator, as the COCO substrate, with private climate automation and fertility through dosatron. “This site is built of reliability and volume,” explained Natchak. “We are able to produce consistently on a scale and maintain competitive costs while export standards are maintained.”

Coco, adds, is a practical opportunity for large-scale production in Thailand. “The substrate is more forgiveness.” With a strong Thai agricultural base, the Coco supply is not a problem, despite the global lack of this current media. “We promise about the baht of the top 200,000 Baht in Baht, and is not a shortage for us. We are a country of agriculture with coconut production.”

© World Pharma Solutions

Samut Sakhon, stress houses produces 40-50 kg a week with a different crop philosophy. Here, the plants grow in Rockwool’s eight flowering rooms, managed by a small and specialized group of vineyards. “Rockwool is more suitable for craft approaches,” he explains. “Thai vines have a greater experience, especially those who have learned from American crop practice. The smaller bedroom allows us to run accurately.”

The site also has pheno-feno-hunting, mother stock and post-harvest processes. “We look for the strongest plants of mother, resistant to plague, not brittle, adaptable and high performance. That is the spine of everything we do,” he added. Homemade pathogen tests (HLV, fusarium) supports this program, with full climate control and well-managed drying and healing work flows.

The two facilities work completely inside LED lighting. With Natch, it has been a clear option: In a Thai climate, the internal crop provides full environmental control. To access European markets, strict microbial standards must be complied with, something difficult in external or greenhouse configurations, due to surprises and insect pressures.

© World Pharma Solutions

Thai market developments
Compared to business, the Thai cannabis sector is still at the beginning of the development phase. While the interest in dispensers in products like gums and editors are growing, the rules that require a prescription have affected the rhythm of retail growth. ‘Owners and operators live in different ways of market, so the perspectives can change as he asks,’ Natcha notes. After all, the winners do not see the regulations as obstacles, but as a basis for building permanent business models

His attitude, however, is clear: building international standards, although the demand for home remains uncertain. “Initially, I was looking at Europe and Canada as a model. Players who cut corners do not last long. For us, I had to fill it from one day to the next day.”

“The competitive advantage of Thailand lies in production costs, but the quality remains priority. Some non-compliance flowers made this year before, which does not meet farm rules,” Natcha says. “We want to show that Thailand can compete with international producers at the same quality level.”

© World Pharma Solutions

Through the work done with a local association, Natcha is being pushed in Thailand to implement as a credible exporter. “We want to work with the government, not working against it. Compared to other countries. But if it hurts in Thailand’s popularity, the government will act quickly.

This is an illegal space for a sector that has the greatest importance was illegal and now is done to a standard that is not supported by error. “It takes years to destroy fame and minutes,” says natchak. “We have a long term. This means consistency, fulfilling and proving that Thailand can compete globally.”

For more information:
World Pharma Solutions
98/20, 1 Bang Sao Tong Subdistrict, Bang Sao Thong District, Samut Prakan Province 10570, Thailand
+ 6662-718-6756
(Protected by email)
worldpharmasolutions.com

Related Topics:
Continue Reading

Cannabis News

Greenhouses and more at Fruit Logistica Berlin

Published

17 hours ago

on

February 9, 2026

By











New varieties, new concepts, new packaging, new products, new faces – there was a lot to do in Berlin last week. And, new travel schedules too: due to the black ice, many visitors traveling by plane had to extend their stay or find an alternative mode of transport – or both.

Click here for the photo report.

© Arlette Sijmonsma | MMJDaily.com

Fortunately, our bus drivers got us home safely to the Netherlands, and we were able to take all the photos of the greenhouse suppliers, growers and other related parties, so take a seat and enjoy our Fruit Logistica photo report!

There will be more updates this week, as well as extensive reports from our international Freshplaza colleagues, focused on the fresh produce industry.

Click here for the photo report.










Continue Reading

Cannabis News

Alaska Government Task Force Recommends Legalizing Psychedelic Therapy Upon FDA Approval

Published

17 hours ago

on

February 9, 2026

By

An Alaska psychedelic task force is recommending that the state move forward with plans to provide regulated access to psychedelics if the federal Food and Drug Administration (FDA) allows medical use of substances such as psilocybin and MDMA.

According to a law approved in 2024, after working for about a year studying the issue, Alaska Legislative Task Force on Psychedelic Drug Regulation released its findings and recommendations on Thursday.

“Alaska has one of the nation’s highest rates of domestic violence survivors and combat veterans suffering from PTSD, and many Alaskans continue to struggle with traditional treatments,” Sen. Forrest Dunbar (D), the task force’s leader, said in a press release.

“Our approach to these new medical therapies must be properly and independently evaluated so that if the legislature were to make policy changes, we will do so with empirical data in a properly controlled environment,” the senator said.

The panel’s report lists a number of findings based on a review of the scientific literature and expert testimony. This includes findings that some psychedelics do indeed have “potential therapeutic uses” and that “there is a particular focus on the use of these therapies for veterans, survivors of assault and interpersonal violence, and others with post-traumatic stress disorder (PTSD).

Members emphasized the importance of delivering psychedelic therapies in partnership with “multiple types of providers” to provide comprehensive treatment, rather than leaving it up to the patient.

Among its recommendations, the task force said, “If psychedelic medical therapies are approved by the FDA, the state should take steps to allow them to be used in Alaska, rather than ban their use.”

Alaska regulators should also identify clinical task forces, “whose role is to regularly review up-to-date studies and the evidence base to make recommendations, and rely on those entities to provide ongoing guidance on the use of these therapies,” he said.

“As much as possible, reserve the use of state statute for broad enabling language and essential components of a regulatory structure, and leave most regulatory decisions to the appropriate boards and agencies,” another recommendation reads. “Regulations still require a robust public process to be approved, but they are more predictable and can be updated or changed more easily than statutory amendments that require legislative action.”

“The appropriate parameters for the use of these therapies are likely to change over time as the evidence base matures and FDA approval may be granted for multiple therapies,” he said.

If the FDA continues to approve any psychedelics for medical use, the panel said the Alaska State Board of Medicine should update its guidelines for prescribing controlled substances to include new therapies.

Additionally, if the FDA approves psychedelic drugs and the Drug Enforcement Administration (DEA) federally reschedules substances such as psilocybin, Alaska “should fully reflect federal programming and Risk Evaluation and Mitigation Strategies (REMS), without adding duplicative or conflicting state regulations, and follow the rules for determining whether a DEA license is required.” the report he says

“This approach respects federal science and facilitates access for patients and providers,” he continues.

Additionally, as lawmakers and regulators await a federal decision to advance psychedelic therapies, states should consider legislation to “incorporate the recommendations made in this report to encourage statewide implementation action.”

“Legislation on triggers would require addressing various process and regulatory issues, such as the role and involvement of professional licensing boards, state agencies, and the Controlled Substances Advisory Committee,” the task force said.

The report also says that psychedelic reform should include military veterans’ access to FDA-approved therapies, which could involve working with the US Department of Veterans Affairs (VA) to identify opportunities to participate in clinical trials and pilot programs using new drugs.

“The grant should be considered to ensure active efforts by the American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) to develop billing codes that will promote sufficient reimbursement for the provision of psychedelic therapy, which are essential to ensure patient access post-FDA approval,” the panel said.

Rep. Justin Ruffridge (R), who also serves as co-chair of the psychedelic panel, said the task force “focused on preparing Alaska for potential federal approval of psychedelic therapies.”

“These recommendations came from months of collaboration and work by medical professionals, advocates and legislators who focused on patient safety, evidence-based care and access, especially for those who have not seen progress through traditional treatments,” he said.

So far two other states have facilitated fully functioning psychedelic programs. Oregon voters legalized the therapeutic psilocybin in 2020and Colorado’s program was approved at the ballot box in 2022, with the state’s governor signing the legislation a year later to create the regulatory framework for the program

Meanwhile, a campaign in Alaska announced in December that it did not get enough signaturesAn initiative to legalize some psychedelics like psilocybin and DMT on the 2026 state ballot.– but the activists have emphasized that “the work is far from over” as they focus on putting the reform measure before the voters in 2028.

“While we won’t be on the ballot in 2026, we’re still on track for 2028, and with the determination, focus and support of our community, we’ll continue to move forward,” Natural Medicine Alaska said in December. “This movement is gaining momentum every day. In fact, 65 percent of Alaskans support this initiative, and that number continues to grow.”

A pre-campaign policy outline explained that the proposal is “under construction”. The Natural Medicine Health Act of 2022 passed by Colorado votersunder last year facilitators administered the state’s first legal dose of psilocybin.

A 2024 poll found that nearly half (49.4 percent) of Alaskan adults would support a ballot measure more broadly. remove criminal penalties for the use of substances such as psilocybin mushrooms.

That support rose significantly—to nearly two-thirds (65 percent)—when participants were told that Alaska has high rates of mental illness that could be treated with psychedelics.

Photo elements courtesy of the user carlosemmaskype and Apollo.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Anti legalization group fails to collect signatures to roll back laws

Published

2 days ago

on

February 8, 2026

By











A Maine campaign seeking to significantly roll back the state’s marijuana law failed to submit signatures this week for the November 2026 ballot, meaning anti-cannabis activists will have to move to 2027 if they hope to get the issue before voters.

Amid criticism from reform advocates, industry players and some lawmakers for allegedly deceptive signature-gathering tactics, Mainers for a Safe and Healthy Future apparently couldn’t make the cut by the Feb. 2 deadline.

“Cannabis orders were not returned yesterday,” Assistant Secretary of State for Communications Jana Spaulding told Cannabis Business Times on Tuesday. In Maine, that doesn’t mean the campaign has to start from scratch, though, because they can still put the proposition on next year’s ballot. A Republican Maine lawmaker and marijuana industry advocates raised the alarm last month that prohibitionist campaigners were using deceptive petitions to get voters to sign the petition.

A video shared by Rep. David Boyer (R) appeared to feature an image and audio recording of a person gathering signatures for the ballot measure, in which he grossly misrepresented what the cannabis proposal would accomplish, saying its main goal was to ensure the product’s safety through improved testing.

Read more at Marijuana Moment










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media